Beta Bionics, Inc.
Ownership
Ownership Structure
Who owns Beta Bionics, Inc. (BBNX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 58.9% of the shares are freely tradable; institutional investors hold 112.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 13.90 | 6,253,673 | +5.2 | 06/30/2026 |
| Soleus Capital Management, L.P. | 9.77 | 4,393,714 | +0.9 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 9.40 | 4,227,634 | +22.2 | 03/31/2026 |
| Sands Capital Ventures, LLC | 8.24 | 3,708,043 | +0.0 | 06/30/2026 |
| Farallon Capital Management, L.L.C. | 8.02 | 3,607,920 | -16.4 | 03/31/2026 |
| BlackRock Inc | 6.75 | 3,038,595 | +4.3 | 03/31/2026 |
| Point72 Asset Management, L.P. | 5.61 | 2,525,040 | +155.7 | 03/31/2026 |
| Vestal Point Capital LP | 4.92 | 2,211,518 | +268.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Eventide Gilead N | 8.86 | 3,983,917 | +6.2 | 06/30/2026 |
| Eventide Healthcare & Life Sciences I | 4.56 | 2,052,176 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Saint Sean | President & CEO | 398,429 | 8,725,595 $ | Sep 3, 2026 | direct |
| Mensinger Mike | Chief Product Officer | 177,390 | 3,884,841 $ | Sep 16, 2026 | direct |
| Russell Steven Jon | Chief Medical Officer | 169,628 | 3,714,853 $ | Sep 2, 2026 | direct |
| Feider Stephen | Chief Financial Officer | 159,378 | 3,490,378 $ | Sep 2, 2026 | direct |
| Hopman Mark | Chief Commercial Officer | 56,479 | 1,236,890 $ | Sep 16, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Mensinger Mike | Chief Product Officer | Sell | 2,650 | 22.00 | 58,300 |
| Sep 16, 2026 | Hopman Mark | Chief Commercial Officer | Sell | 30,779 | 20.13 | 619,640 |
| Sep 14, 2026 | Hopman Mark | Chief Commercial Officer | Sell | 775 | 15.52 | 12,028 |
| Sep 9, 2026 | Hopman Mark | Chief Commercial Officer | Sell | 36,870 | 18.46 | 680,723 |
| Sep 3, 2026 | Saint Sean | President & CEO | Sell | 5,641 | 20.08 | 113,259 |
| Sep 2, 2026 | Russell Steven Jon | Chief Medical Officer | Sell | 4,221 | 19.11 | 80,676 |
| Sep 2, 2026 | Saint Sean | President & CEO | Sell | 16,867 | 19.11 | 322,381 |
| Sep 2, 2026 | Feider Stephen | Chief Financial Officer | Sell | 6,675 | 19.11 | 127,580 |
| Sep 2, 2026 | Mensinger Mike | Chief Product Officer | Sell | 4,375 | 19.11 | 83,620 |
| Sep 2, 2026 | Hopman Mark | Chief Commercial Officer | Sell | 5,327 | 19.11 | 101,815 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.